EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Clinical and Translational Medicine

Table 5 The independent predictive factors for overall survival

Characteristic	HR (95% CI)	P-value	HR^a (95% CI)	P-value^a
EGFR plasma at baseline	3.65 (1.04–12.87)	0.044	6.87 (1.13–41.66)	0.036
Bone metastasis at baseline	2.73 (1.25–5.98)	0.012	14.92 (1.88–96.63)	0.010
Treatment method	1.97 (1.16–3.35)	0.012	5.48 (1.12–26.77)	0.035
New metastasis site	2.99 (1.44–6.21)	0.003	4.63 (1.22–17.61)	0.034
cfDNA	3.23 (1.45–7.20)	0.004	29.67 (3.98–91.36)	< 0.001